Debopam Samanta MDAssociate Professor of Pediatrics and Chief of Child Neurology (Interim), Arkansas Children Hospital (ACH) and University of Arkansas for Medical Sciences (UAMS), Little Rock, Arkansas
Debopam Samanta, MD, is a tenured Associate Professor of Pediatrics and Chief of Child Neurology (Interim) at the Arkansas Children Hospital (ACH) and University of Arkansas for Medical Sciences (UAMS) in Little Rock, AR. Dr. Samanta earned his medical degree with Honors (2004) from Calcutta University and his post-graduate degree in Pediatrics (2007) from Delhi University in India. He pursued his residency training in Pediatric Neurology at the University of Virginia Medical Center (2008-2013), where he received highest academic achievement award in 2011 by the Neurology department. He completed his Clinical Neurophysiology training in UAMS (2013-2014). He is on faculty at the UAMS/ACH for last 6 years, where he is the medical director of tuberous sclerosis clinic, neurometabolic/neurogenetic clinic, and clinical neurophysiology laboratory. He also serves as the interim director of the Epilepsy Monitoring unit and the Division of Child Neurology.
Dr. Samanta has a research interest in the treatment of epilepsy and neurogenetics. He has extensively lectured on the medical treatment of intractable epilepsy and has published his papers in esteemed medical journals. He directs the Pediatric Neuroscience grand round at Arkansas Children hospital and is a reviewer for several academics journals. He is currently certified in four boards with diplomat status in the American Board of Pediatrics, American Board of Neurology with a special qualification in child neurology, American Board of Clinical Neurophysiology, and American Board of Neurology with a special qualification in Epilepsy. Dr. Samanta has been selected as a committee member to the American Clinical Neurophysiology Society (ACNS) and the American Epilepsy Society (AES).
Dr. Debopam Samanta disclosed that he has participated as an investigator in two GW Pharmaceutical-sponsored studies involving Epidiolex. He did not receive any salary support for this participation.